In late June, Pfizer, the nation’s second-largest pharmaceutical supplier, broke ground on BioPlace, a $250 million, 285,000-sf R&D and process development facility in Chesterfield, Mo.

The new campus, when completed in mid 2019, will house the company’s BioTherapeutics Pharmaceutical Sciences Group, and consolidate more than 450 employees who currently work at multiple locations around St. Louis, including some who working out of leased space in Monsanto’s research center.